Factors affecting dietary progression post cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

被引:0
|
作者
Stibbard, Allysha [1 ,2 ]
Brown, Morgan [1 ]
Pons, Rachel [1 ]
Ward, Jessica [2 ]
Page, Naomi [1 ]
Stefoska-Needham, Anita [2 ]
机构
[1] St George Hosp, Dept Nutr & Dietet, Level 2,Pritchard Wing, Kogarah, NSW 2217, Australia
[2] Univ Wollongong, Illawarra Hlth & Med Res Inst, Smart Foods Ctr, Sch Med, Bldg 32,Northfields Ave, Keiraville, NSW 2500, Australia
关键词
HIPEC; Dietary progression; Peritonectomy; Debulking surgery; Parenteral nutrition; Nutrition support; PERITONEAL CARCINOMATOSIS; POSTOPERATIVE ILEUS; NUTRITION;
D O I
10.1016/j.clnesp.2024.06.057
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background & aims: Peritoneal carcinomatosis (PC) is treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Timely postoperative nutrition is required to reduce the risk of malnutrition and other complications; thus the present study aims to evaluate factors that may impact dietary progression following CRS/HIPEC treatment. Methods: Forty-two patients undergoing CRS/HIPEC at a tertiary hospital were audited between April 2019 and August 2020. Patients were classified into two groups: fast dietary progression (FDP) and slow dietary progression (SDP), based on commencement of a full fluid diet (FF) within 7 days or after 7 days postoperatively. Between-group differences in patient characteristics, surgical factors and postoperative complications were evaluated statistically (significant at p < 0.05). Results: FDP and SDP groups comprised of 22 (52%) and 20 (40%) patients, respectively. A FF diet was established on a median of 7 (4.25-9.75) days, but not before day 2. Nineteen of the 31 (61.3%) patients receiving parenteral nutrition (PN) were in the SDP group (p = 0.009). The SDP group had longer surgery duration (p = 0.05), more gastrointestinal anastomoses (GIAs) (p = 0.02), more enterotomies (p = 0.008), higher rates of prolonged ileus (p = 0.007), longer duration to first bowel motion (p = 0.002), more returns to theatre (p = 0.03), higher Clavien Dindo scores >= IIIb (p = 0.01) and longer postoperative length-of-stay (p = 0.001), compared to the FDP group. Conclusions: Postoperative complications were associated with SDP in PC patients undergoing CRS/ HIPEC. Strategies that aim to limit SDP through timely commencement of nutrition, including PN, are important to improve postoperative outcomes in this patient group. Crown Copyright
引用
收藏
页码:520 / 529
页数:10
相关论文
共 50 条
  • [1] Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma
    Tan, Grace H. C.
    Cheung, Michelle
    Chanyaputhipong, Jendana
    Soo, Khee Chee
    Teo, Melissa C. C.
    [J]. ANNALS ACADEMY OF MEDICINE SINGAPORE, 2013, 42 (06) : 291 - 296
  • [2] Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Acs, Miklos
    Babucke, Maximilian
    Jusufi, Maximilian
    Kaposztas, Zsolt
    Slowik, Przemyslaw
    Hornung, Matthias
    Schlitt, Hans J.
    Panczel, Ivan
    Hevesi, Judit
    Herzberg, Jonas
    Strate, Tim
    Piso, Pompiliu
    [J]. INNOVATIVE SURGICAL SCIENCES, 2024, 9 (01): : 3 - 15
  • [3] The quest of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): searching for evidence
    Reymond, Marc A.
    [J]. PLEURA AND PERITONEUM, 2016, 1 (04) : 167 - 168
  • [4] Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Tan, Grace Hwei Ching
    Chia, Claramae Shulyn
    Tan, Sze Huey
    Soo, Khee Chee
    Teo, Melissa Ching Ching
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (05) : 989 - 998
  • [5] Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Grace Hwei Ching Tan
    Claramae Shulyn Chia
    Sze Huey Tan
    Khee Chee Soo
    Melissa Ching Ching Teo
    [J]. International Journal of Clinical Oncology, 2018, 23 : 989 - 998
  • [6] Malignant Struma Ovarii Treated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
    Acs, Miklos
    Haeusler, Sebastian
    Lighvani, Hamid-Reza
    Zustin, Jozef
    Piso, Pompiliu
    [J]. IN VIVO, 2021, 35 (06): : 3591 - 3596
  • [7] Morbidity and mortality of synchronous hepatectomy with cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
    Mouw, Tyler J.
    Lu, Jennifer
    Woody-Fowler, Meghan
    Ashcraft, John
    Valentino, Joseph
    DiPasco, Peter
    Mammen, Joshua
    Al-Kasspooles, Mazin
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (05) : 828 - 832
  • [8] Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
    Gabriel, Emmanuel
    Elli, Enrique
    Bagaria, Sanjay
    Wasif, Nabil
    Grotz, Travis
    Stauffer, John
    Kasi, Pashtoon M.
    Asbun, Horacio
    [J]. JOURNAL OF ROBOTIC SURGERY, 2019, 13 (01) : 175 - 179
  • [9] The use of Hypotension Prediction Index in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
    Gangakhedkar, Gauri R.
    Solanki, Sohan Lal
    Divatia, Jigeeshu, V
    [J]. INDIAN JOURNAL OF ANAESTHESIA, 2022, 66 (04) : 294 - 298
  • [10] Water lavage as an adjunct to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
    Gabriel, Emmanuel
    Singla, Smit
    Kim, Minhyung
    Fisher, Daniel
    Powers, Colin
    Visioni, Anthony
    Attwood, Kristopher
    Skitzki, Joseph
    [J]. AMERICAN JOURNAL OF SURGERY, 2017, 214 (03): : 462 - 467